help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gen, M.
Right arrow Articles by Mori, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gen, M.
Right arrow Articles by Mori, S.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 463-470, Copyright © 1984 by Endocrine Society

ARTICLES

Necrotic changes in prolactinomas after long term administration of bromocriptine

M Gen, T Uozumi, M Ohta, A Ito, H Kajiwara and S Mori

Six prolactinoma patients were studied endocrinologically and their tumors were examined histologically after long term bromocriptine therapy. In patient 1 with a large prolactinoma, a marked reduction in size and a remarkable decrease in elevated serum PRL levels occurred after bromocriptine treatment for 8 months. The histological findings consisted of two components, i.e. shrunken island-like cell nests and acellular spaces. Some degenerative and necrotic tumor cells, hyaline substance, and fibrosis were observed with light and electron microscopy in these acellular spaces. Island-like cell nests consisted of atrophic cells having disproportionally scanty cytoplasm. The same histological findings were observed in four other patients. However, in another patient whose tumor decreased in size only slightly during bromocriptine therapy, the specimen had few acellular spaces. Thus, long term bromocriptine treatment of patients with prolactinomas may result in necrosis of some adenoma cells in some patients.


This article has been cited by other articles:


Home page
 NEJMHome page
A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, and G. Lombardi
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
N. Engl. J. Med., November 20, 2003; 349(21): 2023 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Schlechte
Prolactinoma
N. Engl. J. Med., November 20, 2003; 349(21): 2035 - 2041.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Q. Passos, J. J. S. Souza, N. R. C. Musolino, and M. D. Bronstein
Long-Term Follow-Up of Prolactinomas: Normoprolactinemia after Bromocriptine Withdrawal
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3578 - 3582.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society